PIA
RARE icon

Piedmont Investment Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Piedmont Investment Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-816
Closed -$63K – 1985
2018
Q2 		$63K Buy
+816
New +$52.7K ﹤0.01% 1214

Other funds holding RARE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Piedmont Investment Advisors's RARE Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2018, closing a stake of 816 shares — an estimated $63K sold.

Piedmont Investment Advisors first reported a position in RARE in Q2 2018 and held it in 1 quarter. The position peaked at $63K in Q2 2018. 177 funds tracked by Wall St. Rank hold RARE as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 816 Ultragenyx Pharmaceutical shares in Q3 2018, an estimated $63K.
  • Piedmont Investment Advisors first reported a position in Ultragenyx Pharmaceutical in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Ultragenyx Pharmaceutical position peaked at $63K in Q2 2018.
  • 177 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.